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Background: Extensively drug-resistant (XDR) Pseudomonas aeruginosa and Acineto-
bacter baumannii are a threat to hospitalized patients. We evaluated the effects of antimi-
crobial combinations on XDR P. aeruginosa and A. baumannii isolates.
Methods: P. aeruginosa and A. baumannii isolates, which were resistant to all antibiotics 
except colistin (CL), were collected from eight hospitals in Korea. Genes encoding metallo-
β-lactamases (MBLs) and OXA carbapenemases were detected by PCR in eight P. aerugi-
nosa and 30 A. baumannii isolates. In vitro synergy of antimicrobial combinations was 
tested by using the checkerboard method. 
Results: Minimum inhibitory concentrations of β-lactams, aminoglycosides, and fluoroqui-
nolones were very high, while that of CL was low for majority of XDR P. aeruginosa and A. 
baumannii isolates. Antimicrobial combinations including Imipenem (IPM)-CL, ceftazi-
dime (CAZ)-CL, and rifampin (RIF)-CL exerted only additive/indifferent effects on majority 
of XDR P. aeruginosa isolates. Proportions of XDR A. baumannii isolates that showed syn-
ergistic and additive/indifferent inhibition after treatment with antimicrobial combinations 
used are as follows: IPM-ampicillin-sulbactam (AMS), 17% and 80% isolates, respec-
tively; IPM-rifampin (RIF), 13% and 81% isolates, respectively; IPM-CL, 13% and 87% 
isolates, respectively; and RIF-COL, 20% and 73% isolates, respectively. Significant pro-
portion (19%) of XDR P. aeruginosa isolates produced MBLs, and majority (82%) of A. 
baumannii isolates produced either MBLs or OXA-23.
Conclusions: Our results suggest that combinations of IPM-AMS, IPM-RIF, IPM-CL, and 
RIF-CL are more useful than individual drugs for treating 13-20% of XDR A. baumannii 
infections.
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INTRODUCTION
Glucose nonfermentative gram-negative bacilli (GNFB) such as 
Pseudomonas aeruginosa and Acinetobacter baumannii are op-
portunistic pathogens that cause infections mainly in hospital-
ized patients, especially in patients in intensive care units [1, 2]. 
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Most GNFB are naturally resistant to many antimicrobial agents 
and also acquire antimicrobial resistance easily. Therefore, 
GNFB infections are difficult to treat. 
Carbapenem is the only available drug for treating GNFB in-
fections in many cases. However, the recent increase of car-
bapenem resistance in GNFB has become a serious problem 
worldwide, particularly in Korea [3]. Most carbapenem-resistant 
P. aeruginosa and A. baumannii strains identified in Korea are 
also extensively drug-resistant (XDR) [4]. Few treatment options 
are currently available for treating infections caused by these 
notorious pathogens. Colistin (CL) and polymyxin B can be used 
for treating infections caused by XDR P. aeruginosa and A. bau-
mannii; however, these drugs are associated with severe side 
effects, including nephrotoxicity and neurotoxicity [5]. Moreover, 
identification of appropriate therapeutic concentrations of these 
drugs in the blood is difficult [6, 7]. Tigecycline is another prom-
ising antibiotic [8]. However, it cannot be used for treating P. ae-
ruginosa infections due to natural resistance [9]. Furthermore, 
some researchers have reported the emergence of tigecycline-
resistant A. baumannii in some countries [10, 11]. One classical 
treatment method often used for treating infections caused by 
multi-drug resistant (MDR) pathogens is administration of com-
binations of several antibiotics [12-15]. Some evidence suggests 
that these combinations are effective for treating infections 
caused by XDR GNFB. 
In this study, we determined the extent of synergistic effects 
exerted by antimicrobial combinations on XDR P. aeruginosa 
and A. baumannii isolates collected from hospitals in Korea.
METHODS
In all, 77 XDR GNFB isolates (43 P. aeruginosa and 34 A. bau-
mannii isolates), which were resistant to all tested antibiotics, 
except CL, were collected from eight university hospitals in Ko-
rea in 2007. Antimicrobial susceptibilities of these isolates were 
initially tested at each hospital by using CLSI disk diffusion 
method or Vitek 2 system (bioMerieux, Marcy l’Etoile, France). 
The species of each isolate was determined at a coordinating 
laboratory, and minimum inhibitory concentration (MIC) of each 
antibiotic (piperacillin, piperacillin-tazobactam, ampicillin-sul-
bactam [AMS], cefotaxime, ceftazidime [CAZ], cefepime, aztre-
onam, imipenem [IPM], meropenem, gentamicin, amikacin, 
ciprofloxacin, trimethoprim-sulfamethoxazole, and CL) was de-
termined by using CLSI agar dilution method [16]. 
The ability of each isolate to produce carbapenemases and 
metallo-β-lactamases (MBLs) was screened by Hodge test [17] 
and IPM-EDTA sodium mercaptoacetic acid double-disk synergy 
test [18], respectively. Results of these tests were confirmed by 
PCR to determine the presence of blaVIM, blaIMP, blaSIM, and blaOXA 
(blaOXA-23, blaOXA-24, blaOXA-51, and blaOXA-58) [19]. DNA was ex-
tracted from whole-cell lysates by boiling bacterial colonies. Am-
plification was performed in a 20-μL reaction mixture containing 
1-μL heat-extracted DNA template, 10 pmol of each primer, and 
PreMix (Bioneer, Cheongwon, Korea) containing 1 U Taq DNA 
polymerase. Sizes of amplified products were confirmed by per-
forming electrophoresis, and each confirmed amplified product 
was sequenced twice by using an automatic sequencer (model 
3730xl; Applied Biosystems, Weiterstadt, Germany). 
Checkerboard method was used to determine the degree of 
in vitro synergistic effects exerted by antimicrobial combinations 
used on 30 randomly selected isolates of XDR P. aeruginosa 
and A. baumannii each [20]. Antimicrobial combinations tested 
were IPM and CL, rifampin (RIF) and CL, and CAZ and CL for P. 
aeruginosa and IPM and CL, IPM and AMS, IPM and RIF, and 
RIF and CL for A. baumannii. Fractional inhibitory concentration 
index (FICI) was calculated by using the following formulae:
FICA =MIC of drug A in combination/MIC of drug A alone
FICB =MIC of drug B in combination/MIC of drug B alone
FICI=FICA+FICB
FICI were interpreted as follows: ≤0.5, synergistic effect; 0.5-
4, additive/indifferent effect; and ≥4, antagonistic effect. Esche-
richia coli (ATCC 25922) and P. aeruginosa (ATCC 27853) 
strains were used for quality control.
RESULTS
None of the XDR GNFB isolates examined was susceptible to 
any of the tested antibiotic, except CL. The MICs of β-lactams, 
aminoglycosides, and fluoroquinolones were very high for ma-
jority of XDR P. aeruginosa and A. baumannii isolates (Table 1). 
However, 38% (3/8) of MBL-producing P. aeruginosa isolates 
were intermediately sensitive to aztreonam and 86% (6/7) of 
OXA-23-negative A. baumannii isolates were intermediately sen-
sitive to IPM. 
Of the 43 XDR P. aeruginosa isolates, four were IMP-1- and 
VIM-2-producing isolates. Of the 34 XDR A. baumannii isolates, 
two were IMP-1-, VIM-2-, and SIM-1-producing isolates. Most 
MBL-negative XDR A. baumannii isolates yielded positive results 
for blaOXA-23 (82%), and all the A. baumannii isolates yielded 
positive results for blaOXA-51. 
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In the synergy test, FICI values for the antimicrobial combina-
tions used could not be calculated for three P. aeruginosa iso-
lates and five A. baumannii isolates because their MICs ex-
ceeded the expected values. Three antimicrobial combinations 
exerted only additive/indifferent effects on all XDR P. aeruginosa 
isolates irrespective of their MBL production status (Table 2). 
Proportions of XDR A. baumannii isolates that showed synergis-
tic and additive/indifferent inhibition after treatment with the an-
timicrobial combinations used are as follows: IPM-AMS, 17% 
and 80% isolates, respectively; IPM-RIF, 13% and 81% iso-
lates, respectively; IPM-CL, 13% and 87% isolates, respectively; 
and RIF-CL, 20% and 73% isolates, respectively (Table 3). Most 
A. baumannii isolates that showed synergistic inhibition pro-
duced MBLs. The extent of decrease of MICs in A. baumannii 
isolates ranged from one quarter to one sixteenths (FICI, 0.25-
5). MICs of most antimicrobial concentrations tested decreased 
from high-level resistance range to susceptible and intermediate 
range (Table 4). None of the tested combinations exerted antag-
onistic effects.
DISCUSSION
The recent increase in XDR GNFB infections in health-care set-
tings has threatened public health in many countries. In Korea, 
Table 1. Antimicrobial susceptibilities of extensively drug-resistant P. aeruginosa and A. baumannii isolates
Antibiotic
Pseudomonas aeruginosa (N=43) Acinetobacter baumannii (N=34)
MIC (μg/mL) Susceptibility (%) MIC (μg/mL) Susceptibility (%)
Range 50% 90% S I R Range 50% 90% S I R
Piperacillin 128 to >256 >256 >256 0 0 100 >256 >256 >256 0 0 100
Piperacillin-Tazobactam 128 to >256 >256 >256 0 0 100 >128 >128 >128 0 0 100
Ampicillin-Sulbactam NT 32 to >128 64 >128 0 0 100
Cefotaxime NT >128 >128 >128 0 0 100
Ceftazidime 16 to >128 64 >128 0 0 100 128 to >128 128 >128 0 0 100
Cefepime 32 to >128 128 >128 0 0 100 32 to >128 >128 >128 0 0 100
Aztreonam 16 to >128 128 >128 0 19   81 NT
Imipenem 8 to >128 32 32 0 12   88 8-32 32 32 0 6   94
Meropenem 8 to >128 >128 >128 0 2   98 32-64 32 64 0 0 100
Gentamicin 64 to >128 >128 >128 0 0 100 >128 >128 >128 0 0 100
Amikacin 32 to >128 >128 >128 0 0 100 >128 >128 >128 0 0 100
Ciprofloxacin 8 to >128 32 64 0 0 100 32-128 64 128 0 0 100
Trimethoprim-Sulfamethoxazole NT 16 to >128 128 >128 0 0 100
Colistin 0.5-1 0.5 1 100 - 0 0.5-1 0.5 1 100 - 0
Abbreviations: MIC, minimum inhibitory concentration; NT, not tested; R, resistant; I, intermediate; S, susceptible.
Table 2. Effects of antimicrobial combinations on extensively drug-resistant P. aeruginosa isolates
MBL type
N of
tested
N of isolates (%) with synergistic effect on 
Imipenem-Colistin* Ceftazidime-Colistin† Rifampin-Colistin
Syn Ad/In Ant Syn Ad/In Ant Syn Ad/In Ant
MBL negative 22 0 (0) 22 (100) 0 (0) 0 (0) 22 (100) 0 (0) 0 (0) 22 (100) 0 (0)
MBL positive 8 0 (0) 7 (88) 0 (0) 0 (0) 8 (100) 0 (0) 0 (0) 8 (100) 0 (0)
IMP positive 4 0 (0) 4 (100) 0 (0) 0 (0) 4 (100) 0 (0) 0 (0) 4 (100) 0 (0)
VIM positive 4 0 (0) 3 (75) 0 (0) 0 (0) 4 (100) 0 (0) 0 (0) 4 (100) 0 (0)
Total 30 0 (0) 29 (96) 0 (0) 0 (0) 28 (93) 0 (0) 0 (0) 30 (100) 0 (0)
*FICI value of one strain in the VIM-positive group could not be calculated; †FICI values of two strains in the MBL-negative group could not be calculated.
Abbreviations: FICI, fractional inhibitory concentration index; Syn, synergistic (FICI, ≤0.5); Ad/In, additive/indifferent (FICI, 0.5-4); Ant, antagonistic (FICI, 
≥4); MBL, metallo-β-lactamase.
Lee H, et al.
In vitro synergy of antimicrobial combinations
http://dx.doi.org/10.3343/alm.2016.36.2.138 www.annlabmed.org  141
Table 3. Effects of antimicrobial combinations on extensively drug-resistant A. baumannii isolates
Carbapenemase type
N of
tested
N of isolates (%) with synergistic effect on 
Imipenem-Ampicillin-
Sulbactam*
Imipenem-Rifampin† Imipenem-Colistin Rifampin-Colistin†
Syn Ad/In Ant Syn Ad/In Ant Syn Ad/In Ant Syn Ad/In Ant
MBL negative 24 1 (4) 22 (92) 0 (0) 1 (4) 23 (96) 0 (0) 2 (8) 22 (92) 0 (0) 3 (13) 21 (87) 0 (0)
OXA-23 positive 16 1 (6) 15 (94) 0 (0) 1 (6) 15 (94) 0 (0) 2 (13) 14 (87) 0 (0) 3 (18) 13 (82) 0 (0)
OXA-23 negative 8 0 (0) 7 (88) 0 (0) 0 (0) 4 (50) 0 (0) 0 (0) 8 (100) 0 (0) 0 (0) 8 (100) 0 (0)
MBL positive 6 4 (67) 2 (33) 0 (0) 3 (50) 1 (17) 0 (0) 2 (33) 4 (67) 0 (0) 3 (50) 1 (17) 0 (0)
IMP positive 2 1 (50) 1 (50) 0 (0) 1 (50) 1 (50) 0 (0) 1 (50) 1 (50) 0 (0) 2 (100) 0 (0) 0 (0)
VIM positive 2 2 (100) 0 (0) 0 (0) 2 (100) 0 (0) 0 (0) 1 (50) 1 (50) 0 (0) 1 (50) 1 (0) 0 (0)
SIM positive 2 1 (50) 1 (50) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (100) 0 (0) 0 (0) 0 (0) 0 (0)
Total 30 5 (17) 24 (80) 0 (0) 4 (13) 24 (81) 0 (0) 4 (13) 26 (87) 0 (0) 6 (20) 22 (73) 0 (0)
*FICI value of one isolate in OXA-23-positive group could not be calculated; †FICI values of two isolates in SIM-positive group could not be calculated.
Abbreviations: FICI, fractional inhibitory concentration index; Syn, synergistic (FICI, ≤0.5); Ad/In, additive/indifferent (FICI, 0.5-4); Ant, antagonistic (FICI, 
≥4); MBL, metallo-β-lactamase.
Table 4. Concentrations of antibiotic combinations that exerted synergistic effects on extensively drug-resistant A. baumannii isolates
Combination 
   (N of isolates tested)
Strain No.
MICs of individual antimicrobials
(μg/mL)
MICs in combination
(μg/mL)
Effect of 
combination
Imipenem-Colistin (4) Imipenem Colistin Imipenem Colistin FICI
9 32 2 4 1 0.375
11 16 2 4 1 0.5
25 32 0.5 8 0.12 0.5
26 64 4 8 0.5 0.25
Imipenem-Ampicillin-Sulbactam (6) Imipenem Ampicillin-Sulbactam Imipenem Ampicillin-Sulbactam FICI
19 32 64 8 16 0.5
25 32 >128 8 32 0.5
27 32 8 8 1 0.375
28 8 4 2 1 0.5
29 16 4 4 1 0.5
30 64 8 16 2 0.5
Imipenem-Rifampin (4) Imipenem Rifampin Imipenem Rifampin FICI
12 64 32  16  8 0.5
25 32  4  8  0.5 0.375
28 16  8  4 2 0.5
29 16  4  1 1 0.3125
Rifampin-Colistin (6) Rifampin Colistin Rifampin Colistin FICI
2 4 0.5 1 0.12 0.5
9 32 2 1 0.5 0.156
11 32 1 8 0.25 0.5
25 4 0.5 1 0.12 0.5
26 64 2 8 0.5 0.375
29 4 0.5 0.5 0.12 0.375
Abbreviations: MIC, minimum inhibitory concentration; FICI, fractional inhibitory concentration index. 
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the recent rates of carbapenem resistance are moderate to high 
for P. aeruginosa and A. baumannii. Moreover, MDR and XDR P. 
aeruginosa and A. baumannii isolates are commonly identified 
in Korea. Carbapenem resistance can result from enzyme pro-
duction, porin loss, and active efflux. However, it is difficult to 
determine the exact mechanisms underlying carbapenem resis-
tance, except enzyme production. Mechanisms underlying car-
bapenem resistance could not be determined for most P. aeru-
ginosa isolates, except eight (19%) MBL-producing isolates (Ta-
ble 2). Porin loss and active efflux might be the reasons for car-
bapenem resistance in most P. aeruginosa isolates examined in 
this study. Majority of XDR A. baumannii isolates produced 
β-lactamases, including MBLs and OXA-23 (Table 3). 
Polymyxin B and polymyxin E (CL) are regarded as the last 
resort for treating infections caused by MDR or XDR gram-neg-
ative pathogens because of the recent spread of antibiotic resis-
tance in many gram-negative bacilli even though severe toxicity. 
Two studies have suggested that polymyxin B and CL are good 
treatment options because many XDR P. aeruginosa and A. 
baumannii isolates were susceptible to these drugs [21, 22], 
which was consistent with the present results (Table 1). Resis-
tance to polymyxins has been rarely observed recently; however, 
several mechanisms through which bacteria may acquire resis-
tance to polymyxin B and CL have been proposed [23, 24]. A 
study by Matthaiou et al. [25] showed a relationship between 
inappropriate use of CL and development of resistance in P. ae-
ruginosa and A. baumannii. Furthermore, Kim et al. [26] re-
cently reported that mutations in pmrB could induce in vivo 
emergence of CL resistance in A. baumannii clinical isolates of 
sequence type 357. Thus, the threat of increasing resistance to 
polymyxin B and CL is a problem because these drugs need to 
undergo susceptibility testing before their use in clinical settings. 
Moreover, limitation of susceptibility method to these drugs may 
be problematic in clinical microbiology laboratories [27, 28]. 
Treatment with polymyxin B and CL has resulted in frequent 
nephrotoxicity and neurotoxicity, especially in patients with dete-
riorated renal function. Therefore, close monitoring and caution 
are often requested during their use. Combination therapy with 
antibiotics is often used for treating infections caused by MDR 
or XDR pathogens [12-15]. Because antimicrobial combinations 
exerting synergistic effects enable the use of reduced concen-
trations of individual drugs, such combinations may decrease 
the possible toxicities associated with high drug concentrations. 
Polymyxins act primarily on the cell wall by inducing rapid 
changes in the permeability of the cytoplasmic membrane of 
gram-negative bacilli, thereby permitting the entry of other anti-
microbial agents into the cell. Various antimicrobial agents can 
be used in combination with CL. Antibiotics that are most fre-
quently combined with CL include β-lactam antibiotics such as 
carbapenem and RIF. Landman et al. [29] reported that the 
combination of polymyxin B with IPM or RIF exerted synergistic 
effects in 80% and 90% cases, respectively, in a time-kill study 
on P. aeruginosa. In a study by Gunderson et al. [30], the com-
bination of CL with CAZ exerted synergistic effects on two CL-
susceptible MDR P. aeruginosa isolates. However, inconsistent 
results have been obtained by using the combination of car-
bapenems with CL for treating infections caused by MDR P. ae-
ruginosa. Two studies have found that the combination of CL 
with meropenem only exerted additive/indifferent effects on 
MDR P. aeruginosa [31, 32]. A recent meta-analysis by Zusman 
et al. [15] involving 39 publications and 15 conference pro-
ceedings related to the in vitro examination of the combinations 
of polymyxins with carbapenems  showed that the combination 
of polymyxins with IPM exerted synergistic effects on 60% P. 
aeruginosa isolates tested and antagonistic effects on 21% P. 
aeruginosa isolates tested. 
Use of combination therapy can suppress the development of 
resistance in vitro. In this study, both IPM-CL and CAZ-CL only 
exerted additive/indifferent effects and did not exert synergistic 
effects on all XDR P. aeruginosa isolates irrespective of their 
MBL production status (Table 3). The combination of CL with 
RIF is generally recommended in regimens for treating infec-
tions caused by MDR and XDR gram-negative pathogens. How-
ever, the rates of synergy exerted by RIF-CL against different P. 
aeruginosa isolates ranged from 5.7% (2/35) to 16.6% (1/6) 
[31, 33]. Moreover, RIF-CL did not exert synergistic effects on 
any P. aeruginosa isolate in the present study (Table 2). The 
reason for this discrepancy is unknown, and further evaluation 
may be required to completely determine the effect of RIF-CL 
on various P. aeruginosa isolates.
The combination of sulbactam, which is effective against A. 
baumannii [34], with IPM exerted a synergistic effect on ap-
proximately 17% (5/30) XDR A. baumannii, of which four iso-
lates produced MBLs. RIF exhibits bactericidal activity against A. 
baumannii in vitro. A study by Timurkaynak et al. [31] showed 
that 64% of 25 MDR A. baumannii isolates were susceptible to 
RIF. Combinations of RIF with β-lactam antibiotics were effective 
in mouse model of A. baumannii-induced pneumonia [35, 36]. 
However, IPM-RIF only exerted a synergistic effect on as low as 
13% (4/30) XDR A. baumannii isolates in our study. Many stud-
ies have shown that CL monotherapy is effective against MDR 
and XDR A. baumannii and that CL-RIF exerts synergistic and 
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bactericidal effects [37, 38]. In this study, the rates of synergy 
exerted by IPM-RIF and RIF-CL were 13% and 20%, respec-
tively (Table 3).
A study conducted in the UK by Wareham et al. [39] reported 
that combinations of polymyxin B with IPM, RIF, or azithromycin 
did not exert any synergistic effect on OXA-23-producing MDR 
A. baumannii isolates. We also observed that the rates of syn-
ergy of antimicrobial combinations were higher in MBL-produc-
ing A. baumannii isolates than in MBL-negative A. baumannii 
isolates (Table 3). However, a recent meta-analysis showed that 
combinations of polymyxins with IPM exerted synergistic effects 
on 56% A. baumannii isolates tested [15]. Among the antimi-
crobial combinations that exerted synergistic effects, MICs of 
IPM, AMS, and RIF decreased from resistant or intermediate 
range to susceptible range (Table 4). Moreover, the MIC of CL 
when used in combination decreased by 2-8 times compared 
with that when used alone. This finding implies that infections 
caused by isolates that are susceptible to the synergistic effects 
of antimicrobial combination can be treated by using conven-
tional treatment regimens even when these isolates are resistant 
to individual drugs. This also means that the possibility of CL 
toxicity can be reduced. A recent retrospective cohort study in-
volving 236 patients with XDR A. baumannii-induced pneumo-
nia found that survival rates (in terms of 28-day mortality) of pa-
tients treated with combinations of CL with sulbactam, tigecy-
cline, or carbapenem were superior to those of patients in the 
control group who were not treated with any active agent against 
XDR A. baumannii [40].
In conclusion, significant proportion of XDR P. aeruginosa iso-
lates produced MBLs and majority of A. baumannii isolates pro-
duced MBL or OXA-23. All the three antimicrobial combina-
tions, i.e., IPM-CL, RIF-CL, and CAZ-CL, exerted additive/indif-
ferent effects on majority of or all XDR P. aeruginosa isolates. 
And, all the four antimicrobial combinations, i.e., IPM-CL, IPM-
AMS, IPM-RIF, and RIF-CL, exerted synergistic or additive/indif-
ferent effects on majority of A. baumannii isolates. However, 
clinical studies should be performed to validate the application 
of these in vitro results in patients because in vitro synergy may 
not be the same as in vivo synergy and to determine the exact 
mechanisms underlying in vivo synergy.
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